Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 2Endometrial Neoplasms 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Recurrence 1Non-hematologic Malignancy 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Neoplasms 1Genital Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Solid Tumors 1Advanced Solid Malignancies 1Advanced Nonhematological Neoplasms 1

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × sapanisertib × Clear all
NCT01118689 2013-08-02

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡